Fidelity Blue Chip Growth (FBGRX)
Nasdaq • Currently up 6.00 (+1.96%) in today's trading session
1 member of Congress has disclosed 3 trades in Fidelity Blue Chip Growth (FBGRX) via STOCK Act filings. The most recent disclosure was a purchase by Sean Casten on 8 September 2023. Aggregate disclosed activity totals roughly $183K in purchases and $175K in sales (midpoint estimates from bracketed disclosure amounts).
Fidelity Blue Chip Growth is currently trading at $311.89, positioned at 91% of its 52-week range ($237.26 – $319.00).
Want to automatically copy Pelosi trades?
Mirror Nancy Pelosi's portfolio with just one click on eToro.
Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.
Past Performance is not an indication of future results.
Fidelity Blue Chip Growth Price History and Technical Analysis
Congressional Trading Activity for FBGRX
| No data | |||||||
Select transactions to view their annotations on the chart
Similar Stocks
Based on congressional trading patterns
Frequently Asked Questions about FBGRX
- Which members of Congress have traded FBGRX?
- 1 member of Congress has disclosed 3 trade in Fidelity Blue Chip Growth (FBGRX) under the STOCK Act: Sean Casten.
- When was FBGRX most recently disclosed by Congress?
- The most recent FBGRX disclosure was a purchase by Sean Casten on 8 September 2023.
- What is the total disclosed congressional trading volume for FBGRX?
- Members of Congress have disclosed approximately $183K in FBGRX purchases and $175K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
- How can I track new congressional trades in FBGRX?
- This FBGRX page updates as soon as new STOCK Act disclosures are filed for Fidelity Blue Chip Growth. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Track FBGRX in Congress
See when politicians buy or sell this stock